NanoHarmonics acquires Avagen Pharma

By The Science Advisory Board staff writers

March 30, 2022 -- Biodiagnostic device company NanoHarmonics has acquired Avagen Pharma, a global distributor of a product that utilizes an advanced drug delivery system to treat premature ejaculation.

For NanoHarmonics, the deal furthers its goal of integrating drug delivery systems, according to the vendor. Its current pipeline includes pain medications and drugs for malaria, tuberculosis, and other infectious diseases, including COVID-19.

Terms of the acquisition were not disclosed.

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter